Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

David J. Kwiatkowski, MD, PhD, on Clinical Implications of Neoadjuvant Atezolizumab for Resectable Non–Small Cell Lung Cancer

Posted: Sunday, June 2, 2019

David J. Kwiatkowski, MD, PhD, of Brigham and Women’s Hospital and Dana-Farber Cancer Institute, discusses the clinical implications of later lines of therapy if a checkpoint inhibitor is used in the neoadjuvant setting for resectable non–small cell lung cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.